Diabetes, Healthy
Conditions
Brief summary
The trial is conducted in Europe. The aim of the trial is to investigate the influence of semaglutide on the pharmacokinetics (the exposure of the trial drug in the body) of single doses of atorvastatin and digoxin in healthy subjects.
Interventions
DRUGsemaglutide
Administered as a subcutaneous injection (s.c., under the skin). Initiated with weekly semaglutide dosing of 0.25 mg in the first 4 weeks, 0.5 mg the next 4 weeks, and 1.0 mg in the third 4 week period.
DRUGdigoxin
Oral administration. Digoxin will be given as 2 single doses of 0.5 mg.
DRUGatorvastatin
Oral administration. Atorvastatin will be given as 2 single doses of 40 mg.
Sponsors
Novo Nordisk A/S
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Male and female, age between 18 and 55 years (both inclusive) at the time of signing informed consent * Body mass index between 20.0 and 29.9 kg/m\^2 (both inclusive)
Exclusion criteria
* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method. Women of child-bearing potential must use an effective method of birth control throughout the trial including the 5 weeks follow-up period. Only highly effective methods of birth control are accepted (i.e. one that results in less than 1% per year failure rate when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine device), or sexual abstinence or vasectomised partner * Any clinically significant disease history, in the opinion of the investigator, or systemic or organ disease including: cardiac, pulmonary, gastrointestinal, hepatic, neurologic, renal, genitourinary and endocrine, dermatologic or hematologic diseases * Use of prescription or non-prescription systemic or topical medicinal products (including routine or non-routine vitamins or herbal supplements, but excluding paracetamol and contraceptives) within 3 weeks (or within 5 half-lives of the medicinal product, whichever is longest) prior to Visit 2 (first dose administration) * History of drug/chemical substance abuse within 1 year from screening, or a positive result in the urine drug test * History of alcohol abuse within 1 year from screening, or a positive result in the alcohol urine test, or consumption of more than 21 units (male)/14 units (female) of alcohol weekly (one unit of alcohol equals about 250 mL of beer or lager, one glass (120 mL) of wine, or 20 mL spirits) * Smoking in the last 3 months prior to screening or a positive nicotine test
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the atorvastatin plasma concentration-time curve | From time 0 to 72 hours after a single dose |
| Area under the digoxin plasma concentration-time curve | From time 0 to 120 hours after a single dose |
Secondary
| Measure | Time frame |
|---|---|
| Maximum observed atorvastatin plasma concentration | From time 0 to 72 hours after a single dose |
| Maximum observed digoxin plasma concentration | From time 0 to 120 hours after a single dose |
| Number of treatment emergent AEs (TEAEs) | From baseline (Visit 2, Day 1) to follow-up (Visit 12, 20 weeks after baseline) |
Countries
Germany
Outcome results
None listed